ContraFect (NASDAQ:CFRX) Share Price Crosses Above Fifty Day Moving Average of $1.42

ContraFect Co. (NASDAQ:CFRX – Get Rating) shares crossed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.42 and traded as high as $2.09. ContraFect shares last traded at $1.91, with a volume of 155,979 shares changing hands.

Analyst Ratings Changes

Separately, StockNews.com raised ContraFect to a “sell” rating in a research report on Friday, March 10th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, ContraFect has a consensus rating of “Hold” and an average target price of $3.00.

ContraFect Price Performance

The firm has a 50-day moving average price of $1.42 and a 200-day moving average price of $0.60.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Envestnet Asset Management Inc. purchased a new stake in shares of ContraFect in the 1st quarter worth approximately $41,000. Dimensional Fund Advisors LP grew its stake in shares of ContraFect by 62.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 112,782 shares of the biotechnology company’s stock worth $412,000 after buying an additional 43,564 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of ContraFect by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 1,551,898 shares of the biotechnology company’s stock worth $5,664,000 after buying an additional 11,064 shares during the last quarter. State Street Corp grew its stake in shares of ContraFect by 33.5% in the 1st quarter. State Street Corp now owns 129,817 shares of the biotechnology company’s stock worth $474,000 after buying an additional 32,563 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its stake in shares of ContraFect by 1.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 407,031 shares of the biotechnology company’s stock worth $1,486,000 after buying an additional 4,948 shares during the last quarter. Institutional investors own 27.34% of the company’s stock.

ContraFect Company Profile

(Get Rating)

ContraFect Corp. is a clinical stage biotechnology company, which engages in the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its product pipeline consists of CF-301, Gram-Negative Lysins, and Amurin Peptides.